Загрузка...
OS2.8 Survival gain and immune response in glioblastoma patients treated with dendritic cell immunotherapy before and during adjuvant temozolomide
BACKGROUND: While immunotherapy is emerging as adjunctive treatment for brain cancer, sensitive method of monitoring the immune response after therapy remains to be established. In the two stage phase I-II study DENDR-I, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendri...
Сохранить в:
| Опубликовано в: : | Neuro Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5782518/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now188.018 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|